#DIA22: Fireside chat with Zachary Brennan and Aaron Kesselheim
Zachary Brennan:
Hi, good afternoon. Welcome to Endpoints DIA 2020. We are joined at this afternoon’s fireside chat with a special guest, Harvard Professor of Medicine, Aaron Kesselheim. If you follow the FDA closely, you’ve probably come across Aaron’s research frequently, but I wanted to begin today’s discussion because I think a lot of the reason we’re talking about accelerated approval reforms and FDA reforms over the next five years are linked to a recently approved drug that has been very controversial, known as Biogen’s Aduhelm, which is a treatment for Alzheimer’s disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
